PRDX6 and ovarian carcinoma: In addition, Kalinina et al. [75] demonstrated that there was a significant increase in the expression of PRDX1, PRDX3, and PRDX6 in cisplatin-resistant ovarian cancer cell lines when compared with their sensitive counterparts, implying that these isoforms might play an important role in the development of cisplatin resistance of ovarian cancer cells.